PMC:7558914 / 0-723 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"3","span":{"begin":60,"end":84},"obj":"Disease"},{"id":"4","span":{"begin":86,"end":94},"obj":"Disease"},{"id":"5","span":{"begin":99,"end":108},"obj":"Disease"},{"id":"43","span":{"begin":622,"end":640},"obj":"Chemical"},{"id":"61","span":{"begin":199,"end":224},"obj":"Disease"},{"id":"62","span":{"begin":231,"end":239},"obj":"Disease"},{"id":"63","span":{"begin":270,"end":279},"obj":"Disease"},{"id":"64","span":{"begin":312,"end":320},"obj":"Disease"},{"id":"65","span":{"begin":362,"end":371},"obj":"Disease"}],"attributes":[{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A4","pred":"tao:has_database_id","subj":"4","obj":"MESH:C000657245"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D006886"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:C000657245"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:C000657245"},{"id":"A64","pred":"tao:has_database_id","subj":"64","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain\n\nAbstract\nOur objective was to compare clinical protocols for the treatment of the novel coronavirus disease 2019 (COVID-19) among different hospitals in Andalusia, Spain. We reviewed the current COVID-19 protocols of the 15 largest hospitals in Andalusia. Antiviral treatment, empirical antibacterial agents, adjunctive therapies, anticoagulant treatment, supportive care, hospital organization, and discharge recommendations were analyzed. All protocols included were the latest updates as of July 2020. Hydroxychloroquine in monotherapy was the most frequent antiviral drug recommended for mild respirato"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":115},"obj":"Sentence"},{"id":"T2","span":{"begin":117,"end":125},"obj":"Sentence"},{"id":"T3","span":{"begin":126,"end":287},"obj":"Sentence"},{"id":"T4","span":{"begin":288,"end":372},"obj":"Sentence"},{"id":"T5","span":{"begin":373,"end":557},"obj":"Sentence"},{"id":"T6","span":{"begin":558,"end":621},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain\n\nAbstract\nOur objective was to compare clinical protocols for the treatment of the novel coronavirus disease 2019 (COVID-19) among different hospitals in Andalusia, Spain. We reviewed the current COVID-19 protocols of the 15 largest hospitals in Andalusia. Antiviral treatment, empirical antibacterial agents, adjunctive therapies, anticoagulant treatment, supportive care, hospital organization, and discharge recommendations were analyzed. All protocols included were the latest updates as of July 2020. Hydroxychloroquine in monotherapy was the most frequent antiviral drug recommended for mild respirato"}